- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Office of Global Education
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
August 29, 2013
A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies.
The study, published online Aug. 23 in the journal Cancer by researchers at Harvard Medical School, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is the first to compare the spectrum of cancer-related gene mutations in the two main subtypes of cervical cancer—adenocarcinoma and squamous cell carcinoma. In tests on 80 cervical-tumor samples, the investigators found high rates of mutations in two genes: PIK3CA and KRAS. While PIK3CA mutations appeared in both subtypes, KRAS mutations were found only in adenocarcinomas.
By linking their findings to data on patients’ treatment and survival, researchers found that PIK3CA mutations are associated with a shorter survival period: patients whose tumors carried these mutations lived a median of 67 months after diagnosis compared with 90 months for patients whose tumors lacked the mutations.
“We have historically treated cervical cancers as one disease,” said the study’s lead author, Alexi Wright, HMS assistant professor of medicine at Dana-Farber. “However, our findings suggest that some patients may be at higher risk of dying from their disease and might benefit from a more tailored treatment approach.”
The discovery of high rates of PIK3CA mutations in the cervical tumor samples suggests that many patients could benefit from drugs known as PI3-kinase inhibitors, which target the family of proteins associated with the gene, the authors said. Patients with the adenocarcinoma subtype of cervical cancer may benefit from targeted agents known as MEK inhibitors, which have shown some success in clinical trials.
Cervical cancer is the second-leading cause of cancer deaths among women worldwide, responsible for 275,000 deaths annually. While Pap tests have helped decrease the incidence of squamous cell cervical cancer, adenocarcinomas now account for nearly a quarter of all cervical cancers, up from 5 percent 20 years ago.
In the study, investigators probed the DNA of 80 cervical cancer tumors—40 adenocarcinomas and 40 squamous cell carcinomas—for 1,200 mutations in hundreds of genes linked to cancer. The probe was done with OncoMap, a system developed at Dana-Farber to test large numbers of tumor samples for cancer-related genes. They found that 31 percent of the samples had PIK3CA mutations; 17.5 percent of the adenocarcinomas (and none of the squamous cell carcinomas) had KRAS mutations; and 7.5 percent of the squamous cell carcinomas (but none of the adenocarcinomas) had a rare mutation in the gene EGFR.
“While current treatment strategies don’t take into account whether cervical tumors are adenocarcinomas or squamous cell carcinomas, our study suggests that identifying and targeting distinct subsets of patients may improve outcomes for women with early- or late-stage disease,” Wright commented.
The research was supported by grants from the American Cancer Society, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Team Maureen Cervical Cancer Fund and the Friends of Dana-Farber Cancer Institute.
Adapted from a Dana-Farber news release.